## FORM 4

# UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response... 0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. *See* Instruction 1(b).

#### STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

(Print or Ty	pe Response	s)															
Name and Address of Reporting Person * Alvino Mark				2. Issuer Name <b>and</b> Ticker or Trading Symbol ABEONA THERAPEUTICS INC. [ABEO]						EO]	5. Relationship of Reporting Person(s) to Issuer (Check all applicable)  _X_ Director  10% Owner						
(Last) (First) (Middle) 1330 AVENUE OF THE AMERICAS,, 33RD FLOOR					3. Date of Earliest Transaction (Month/Day/Year) 06/06/2022						)	Office	er (give title belo	ow)	Other (specify l	pelow)	
(Street) NEW YORK, NY 10019				4. If	4. If Amendment, Date Original Filed(Month/Day/Year)						6. Individual or Joint/Group Filing(Check Applicable Line)  X_ Form filed by One Reporting Person  Form filed by More than One Reporting Person						
(City) (State) (Zip)					Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned												
1.Title of Security (Instr. 3)		Date (Month/Day/Year)		Execu any	Deemed ution Date,	if Co	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		5. Amount of Securities Beneficially Owned Following Reported Transaction(s)		Following	Ownership Form:	Beneficial		
		(Month/Day/Year)  Code V Amount (D) Pr		Price	Ì				Ownership (Instr. 4)								
Common	Stock		06/06	5/2022				S		35,000	) D	\$ 0.156 (1)	1 47,181			D	
Reminder: 1	Report on a s	separate line	for each		Deriv	ative Secu	rities	Acqui	Per cor the	rsons what intained in form di	ho res in this splays	form a s a curr Benefici	o the collecter not requestion to the collecter of the co	uired to res OMB conf	spond unle	ess	1474 (9-02)
			1		(e.g., ]	puts, calls,	-	ants, o	_							2 4 2	44.37
Security	2. Conversion or Exercise Price of Derivative Security	e (Month/Day	y/Year) Execution		4. Transaction Code Year) (Instr. 8)		of De Se Ac (A Di of (Ir	Number ar		6. Date Exercisable and Expiration Date (Month/Day/Year)		e Ar Ur Se	Title and nount of nderlying curities nstr. 3 and	Derivative Security (Instr. 5)	9. Number of Derivative Securities Beneficially Owned Following Reported Transaction(s (Instr. 4)	Owners Form of Derivati Security Direct ( or Indire	Beneficia Ownersh (Instr. 4)
						Code V	7 (A	A) (D		te ercisable	Expira Date	ation Ti	Amount or Number of Shares				

### **Reporting Owners**

	Relationships					
Reporting Owner Name / Address	Director	10% Owner	Officer	Other		
Alvino Mark 1330 AVENUE OF THE AMERICAS, 33RD FLOOR NEW YORK, NY 10019	X					

#### **Signatures**

/s/ Mark Alvino	06/07/2022	
**Signature of Reporting Person	Date	

#### **Explanation of Responses:**

- \* If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- Reflects the average weighted price of sales on June 6, 2022. The shares were sold in multiple transactions at prices ranging from \$0.155 to \$0.1617, inclusive. The reporting (1) person undertakes to provide Abeona Therapeutics Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within such range.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.